Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
Pediatr Blood Cancer
; 59(5): 939-40, 2012 Nov.
Article
em En
| MEDLINE
| ID: mdl-22492703
ABSTRACT
We report the use of sorafenib and bevacizumab in combination for a patient with recurrent metastatic hepatoblastoma (HB). This combination demonstrated activity against our patient's refractory HB that had been extensively treated with multiple prior chemotherapeutic regimens. The patient had stabilization of radiographic disease coupled with an 83% decrease in his alpha-fetoprotein level. Given the response in this setting and the paucity of other available options, consideration could be given to using this combination as therapy in patients with recurrent HB who have failed more traditional agents.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Benzenossulfonatos
/
Alfa-Fetoproteínas
/
Hepatoblastoma
/
Inibidores da Angiogênese
/
Anticorpos Monoclonais Humanizados
/
Neoplasias Hepáticas
/
Recidiva Local de Neoplasia
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
Limite:
Child, preschool
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article